glp 1 price reduction $350 → $245 → $149: The GLP-1 War Has Begun A Value-Based Price for Anti-Obesity

analyzed commercial claims data (see Figure 2) and found that persistent GLP-1 users had $14K-$15K (about 14%) lower average annual total cost of care in the first one to two years of use compared with chronically obese patients who never tried GLP-1s

Survodutide Dosing# In the Phase 2 obesity trial, survodutide was administered as once-weekly subcutaneous injections at doses of 0.6 mg, 2.4 mg, 3.6 mg, and 4.8 mg

The timing is the strongest clue

It is more effective than most products I have used

We in many of these individuals

From ethical prescribing and dispensing to stronger pharmacovigilance and patient awareness, every stakeholder in healthcare has a role to play